Passage Bio Inc (PASG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.65-2.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PASG
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Operating Expenses & Income | |||||||
| R&D Expenses | 17.2 | 23.3 | 40.2 | 61.4 | — | — | — |
| Operating Income | (39.0) | (49.3) | (70.4) | (108.4) | (138.4) | (185.7) | (112.9) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | — | — | — | — | — | 0.3 | 0.7 |
| Asset Writedown | — | 6.1 | 5.2 | 5.4 | 0.0 | 0.0 | 0.0 |
| Net Income | |||||||
| Net Income | (36.1) | (45.5) | (64.8) | (102.1) | (136.1) | (185.4) | (112.2) |
| Per Share | |||||||
| Basic EPS | (11.25) | (14.35) | (1.07) | (1.86) | (2.50) | (3.48) | (2.91) |
| Diluted EPS | (11.25) | (14.35) | (1.07) | (1.86) | (2.50) | (3.48) | (2.91) |
| Basic Weighted Avg Shares | 3.2 | 3.2 | 60.4 | 54.7 | 54.4 | 53.3 | 38.6 |
| Diluted Weighted Avg Shares | 3.2 | 3.2 | 60.4 | 54.7 | 54.4 | 53.3 | 38.6 |
| Supplemental | |||||||
| EBITDA | — | (48.6) | (67.3) | (104.7) | (134.7) | (184.2) | (112.1) |
| EBIT | (39.0) | (49.3) | (70.4) | (108.4) | (138.4) | (185.7) | (112.9) |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.